rBIO launched with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.
As the world continues to wait for a vaccine against COVID-19, GlaxoSmithKline and Sanofi joined forces to develop an adjuvanted vaccine for COVID-19.
